Context Therapeutics Inc is trading 6.3% down at $2.62 as the stock pulls back from a recent multi-day rally that saw prices rise from approximately $2.40.
- The decline appears driven by short-term profit-taking and consolidation, as no fresh company announcements or sector-wide shocks were reported to explain the move.
- Investors are looking ahead to a major upcoming catalyst: interim Phase 1a CTIM-76 trial data, which is currently scheduled for release in June 2026.